BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

25 related articles for article (PubMed ID: 20701086)

  • 1. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing.
    Sfanos KS; Bruno TC; Maris CH; Xu L; Thoburn CJ; DeMarzo AM; Meeker AK; Isaacs WB; Drake CG
    Clin Cancer Res; 2008 Jun; 14(11):3254-61. PubMed ID: 18519750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer.
    Kaur HB; Guedes LB; Lu J; Maldonado L; Reitz L; Barber JR; De Marzo AM; Tosoian JJ; Tomlins SA; Schaeffer EM; Joshu CE; Sfanos KS; Lotan TL
    Mod Pathol; 2018 Oct; 31(10):1539-1552. PubMed ID: 29849114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Quantification of Radiotherapy-related Protein Expression in Cancer Tissues Using the Qupath Software and Prediction of Treatment Response.
    Hasegawa T; Someya M; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Okuda R; Kaguchi J; Ohguro A; Kamiyama R; Ashina A; Toshima Y; Hirohashi Y; Torigoe T; Sakata KI
    In Vivo; 2024; 38(3):1470-1476. PubMed ID: 38688633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer.
    Davidsson S; Ohlson AL; Andersson SO; Fall K; Meisner A; Fiorentino M; Andrén O; Rider JR
    Mod Pathol; 2013 Mar; 26(3):448-55. PubMed ID: 23041830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral T but not B lymphocytes are related to clinical outcome in prostate cancer.
    Flammiger A; Bayer F; Cirugeda-Kühnert A; Huland H; Tennstedt P; Simon R; Minner S; Bokemeyer C; Sauter G; Schlomm T; Trepel M
    APMIS; 2012 Nov; 120(11):901-8. PubMed ID: 23009114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technical Feasibility of Tissue Microarray (TMA) Analysis of Tumor-Associated Immune Response in Prostate Cancer.
    Wallace TJ; Qian J; Avital I; Bay C; Man YG; Wellman LL; Moskaluk C; Troyer D; Ramnani D; Stojadinovic A
    J Cancer; 2018; 9(12):2191-2202. PubMed ID: 29937939
    [No Abstract]   [Full Text] [Related]  

  • 7. Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells.
    Barakat DJ; Suresh R; Barberi T; Pienta KJ; Simons BW; Friedman AD
    PLoS One; 2018; 13(1):e0191188. PubMed ID: 29324844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
    Hendry S; Salgado R; Gevaert T; Russell PA; John T; Thapa B; Christie M; van de Vijver K; Estrada MV; Gonzalez-Ericsson PI; Sanders M; Solomon B; Solinas C; Van den Eynden GGGM; Allory Y; Preusser M; Hainfellner J; Pruneri G; Vingiani A; Demaria S; Symmans F; Nuciforo P; Comerma L; Thompson EA; Lakhani S; Kim SR; Schnitt S; Colpaert C; Sotiriou C; Scherer SJ; Ignatiadis M; Badve S; Pierce RH; Viale G; Sirtaine N; Penault-Llorca F; Sugie T; Fineberg S; Paik S; Srinivasan A; Richardson A; Wang Y; Chmielik E; Brock J; Johnson DB; Balko J; Wienert S; Bossuyt V; Michiels S; Ternes N; Burchardi N; Luen SJ; Savas P; Klauschen F; Watson PH; Nelson BH; Criscitiello C; O'Toole S; Larsimont D; de Wind R; Curigliano G; André F; Lacroix-Triki M; van de Vijver M; Rojo F; Floris G; Bedri S; Sparano J; Rimm D; Nielsen T; Kos Z; Hewitt S; Singh B; Farshid G; Loibl S; Allison KH; Tung N; Adams S; Willard-Gallo K; Horlings HM; Gandhi L; Moreira A; Hirsch F; Dieci MV; Urbanowicz M; Brcic I; Korski K; Gaire F; Koeppen H; Lo A; Giltnane J; Rebelatto MC; Steele KE; Zha J; Emancipator K; Juco JW; Denkert C; Reis-Filho J; Loi S; Fox SB
    Adv Anat Pathol; 2017 Nov; 24(6):311-335. PubMed ID: 28777143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade.
    Olson BM; Jankowska-Gan E; Becker JT; Vignali DA; Burlingham WJ; McNeel DG
    J Immunol; 2012 Dec; 189(12):5590-601. PubMed ID: 23152566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signalling through FOXP3 as an X-linked tumor suppressor.
    Katoh H; Zheng P; Liu Y
    Int J Biochem Cell Biol; 2010 Nov; 42(11):1784-7. PubMed ID: 20678582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of intratumoral CD8+ regulatory T cells in prostate carcinoma.
    Compérat E; Egevad L; Camparo P; Roupret M; Vaessen C; Valdman A; Jonmarker S; Capron F; Cussenot O; Charlotte F
    Anal Quant Cytol Histol; 2010 Feb; 32(1):39-44. PubMed ID: 20701086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue.
    Valdman A; Jaraj SJ; Compérat E; Charlotte F; Roupret M; Pisa P; Egevad L
    APMIS; 2010 May; 118(5):360-5. PubMed ID: 20477811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
    Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
    Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High intratumoral CD8
    Yang Y; Attwood K; Bshara W; Mohler JL; Guru K; Xu B; Kalinski P; Chatta G
    Prostate; 2021 Jan; 81(1):20-28. PubMed ID: 33085799
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.